Author

Pirmohamed Munir

University of Liverpool - Cited by 59,620 - Clinical Pharmacology - Pharmacogenomics - drug safety - drug hypersensitivity - pharmacovigilance

Biography

Pirmohamed Munir is a professor and scientist Pirmohamed Munir works as a professor,  University of Liverpool - Pharmacology, Sherrington Building Ashton Street - L69 3GE – Liverpool, UK  have research intrest include:-Pharmacogenetics; Pharmacogenomics; Regulatory agencies; Industry; Biomarkers
Title
Cited by
Year
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study
JJ Swen, CH van der Wouden, LEN Manson, H Abdullah-Koolmees, ...The Lancet 401 (10374), 347-356, 2023202
49
2023
The impact of the COVID-19 pandemic on cardiovascular disease prevention and management
CE Dale, R Takhar, R Carragher, M Katsoulis, F Torabi, S Duffield, S Kent, ...Nature medicine 29 (1), 219-5, 2023202
22
2023
Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions
R Osanlou, L Walker, DA Hughes, G Burnside, M PirmohamedBMJ open 12 (7), e055551, 2022202
19
2022
Roadmap to 2030 for drug evaluation in older adults
Q Liu, JB Schwartz, PW Slattum, SWJ Lau, D Guinn, R Madabushi, ...Clinical Pharmacology & Therapeutics 1 (2), 210-223, 2022202
12
2022
Pharmacogenomics: Current status and future perspectives
M PirmohamedNature Reviews Genetics, 1-13, 2023202
12
2023
Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype
RS Gammal, M Pirmohamed, AA Somogyi, SA Morris, CM Formea, ...Clinical Pharmacology & Therapeutics 113 (5), 973-985, 2023202
10
2023
Identifying and visualising multimorbidity and comorbidity patterns in patients in the English National Health Service: a population-based study
V Kuan, S Denaxas, P Patalay, D Nitsch, R Mathur, A Gonzalez-Izquierdo, ...The Lancet Digital Health 5 (1), e16-e27, 2023202
10
2023
Polygenic risk scores: An overview from bench to bedside for personalised medicine
B Cross, R Turner, M PirmohamedFrontiers in Genetics 13, 10007, 2022202
6
2022
Cardiovascular drugs and COVID‐19 clinical outcomes: a systematic review and meta‐analysis of randomized controlled trials
IG Asiimwe, SP Pushpakom, RM Turner, R Kolamunnage‐Dona, ...British Journal of Clinical Pharmacology 88 (8), 377-399, 2022202
5
2022
Pharmacogenomics: relevance and opportunities for clinical pharmacology
RM Turner, EF Magavern, M PirmohamedBritish journal of clinical pharmacology 88 (9), 3943-3946, 2022202
5
2022
Similarity and consistency assessment of three major online drug–drug interaction resources
E Kontsioti, S Maskell, A Bensalem, B Dutta, M PirmohamedBritish journal of clinical pharmacology 88 (9), 067-079, 2022202
4
2022
TNF-α‒Mediated keratinocyte expression and release of matrix metalloproteinase 9: Putative mechanism of pathogenesis in stevens‒johnson syndrome/toxic epidermal necrolysis
A Olsson-Brown, V Yip, ED Ogiji, C Jolly, L Ressel, A Sharma, W Bergfeld, ...Journal of Investigative Dermatology 14 (6), 102-100. e7, 20220
3
2023
Effectiveness of the Med Safety mobile application in improving adverse drug reaction reporting by healthcare professionals in Uganda: a protocol for a pragmatic cluster …
R Kiguba, N Mwebaza, R Ssenyonga, HB Ndagije, V Nambasa, ...BMJ open 12 (7), e061725, 2022202
3
2022
Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions
A Gibson, P Deshpande, CN Campbell, MS Krantz, E Mukherjee, ...Journal of Allergy and Clinical Immunology 151 (2), 289-00. e4, 20220
3
2023
A genome-wide association study of plasma concentrations of warfarin enantiomers and metabolites in sub-Saharan black-African patients
IG Asiimwe, M Blockman, K Cohen, C Cupido, C Hutchinson, B Jacobson, ...Frontiers in pharmacology 13, 96708, 0
2
2022
Leveraging transcriptomics for precision diagnosis: Lessons learned from cancer and sepsis
M Tsakiroglou, A Evans, M PirmohamedFrontiers in Genetics 14, 110035, 030
2
2023
All‐cause and liver‐related mortality risk factors in excessive drinkers: Analysis of data from the UK biobank
JB Whitfield, D Seth, TR Morgan, GenomALC Consortium, GP Aithal, ...Alcoholism: Clinical and Experimental Research 46 (2), 2245-2257, 2022202
1
2022
UK veterinary professionals’ perceptions and experiences of adverse drug reaction reporting
H Davies, G Pinchbeck, PJM Noble, G Diesel, M Pirmohamed, ...Veterinary Record 9 (6), no-no, 2022202
1
2022
Drug–Drug–Gene Interactions in Cardiovascular Medicine
IG Asiimwe, M PirmohamedPharmacogenomics and Personalized Medicine, 879-9, 2022202
1
2022
Combinations of medicines in patients with polypharmacy aged 65–100 in primary care: Large variability in risks of adverse drug related and emergency hospital admissions
Combinations of medicines in patients with polypharmacy aged 65–00 in primary care: Large variability in risks of adverse drug related and emergency hospital admissionsA Fahmi, D Wong, L Walker, I Buchan, M Pirmohamed, A Sharma, H Cant, ...PloS one 8 (2), e028466, 2023202
1
2023

Referred From: https://scholar.google.com/citations?hl=en&user=AY59qbYAAAAJ

Cited by
Citations 59620
h-index 120
i10-index 539
Recommended Journals
Open Access Journals